The Protective Effect of Roflumilast Against Acute Hepatotoxicity Caused by Methotrexate in Wistar Rats: In vivo Evaluation
Drug Design, Development and Therapy · 2024
DOI: 10.2147/dddt.s438703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2024. Verfasst von Riyadh S Almalki. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Umm AL-Qura University, Makkah, Saudi Arabia. Hauptthemen laut MEDLINE: Methotrexate, Chemical and Drug Induced Liver Injury, Aminopyridines, Benzamides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Umm AL-Qura University, Makkah, Saudi Arabia.
ORCID-Profile: Riyadh S Almalki
Zitieren
APA
Almalki, R. S. (2024). The Protective Effect of Roflumilast Against Acute Hepatotoxicity Caused by Methotrexate in Wistar Rats: In vivo Evaluation. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s438703
Vancouver
Almalki RS. The Protective Effect of Roflumilast Against Acute Hepatotoxicity Caused by Methotrexate in Wistar Rats: In vivo Evaluation. Drug Design, Development and Therapy. 2024. doi:10.2147/dddt.s438703
BibTeX
@article{Almalki2024,
author = {Almalki, Riyadh S},
title = {The Protective Effect of Roflumilast Against Acute Hepatotoxicity Caused by Methotrexate in Wistar Rats: In vivo Evaluation},
journal = {Drug Design, Development and Therapy},
year = {2024},
doi = {10.2147/dddt.s438703}
}
EUVIMED